Nam Yun-hee and 124 Co-holders Secure 5.95% Stake in Enzychem Lifesciences... Formation of Shareholder Alliance for Management Influence
A total of 125 individual shareholders, including Nam Yun-hee (the filer), entered into a joint holding agreement, newly holding 5,035,780 common shares (5.95% stake) of Enzychem Lifesciences.
The purpose is to influence management, planning to exercise influence through shareholder proposals and proxy voting on matters such as election/removal of directors, amendments to articles of incorporation, changes in capital, dividend decisions, mergers, business/asset transfers, etc.
Nam Yun-hee holds 256,840 shares (0.30%) in her own name, and together with 124 co-holders, the group holds 5.95%. Major co-holders include Park Chan-kyung (754,000 shares, 0.89%), Lee Sang-heon (506,759 shares, 0.60%), and Im Song-yeop (423,179 shares, 0.50%).
All acquisition funds were self-financed with no borrowings. The total acquisition cost is estimated at approximately 5.12 billion KRW based on individual sums.
The joint holding agreements were signed sequentially from May 15 to May 28, 2026, with no specific contract period stated.
[AI Comprehensive Assessment]The formation of a minority shareholder alliance holding 5.95% to influence management can create positive short-term momentum for the stock price. However, the low stake makes it difficult to force actual changes in control or policy. Future shareholder proposals and potential conflicts with existing management will be key determinants of the stock price direction.